FDA approves updated COVID boosters, but narrows use

In a post on X, HHS Secretary Robert F. Kennedy said the FDA has cleared vaccines from Pfizer, Moderna and Novavax for use in "high risk" individuals.

By Delilah Alvarado • Updated Aug. 27, 2025

A brewing GLP-1 showdown, from Big Pharma pills to a biotech implant

Newcomers looking for a way into the obesity space are developing unique methods to snag market share.

By Amy Baxter • Aug. 27, 2025

Explore the Trendline➔

Artificial intelligence & machine learning

After years of excited buzz around the potential of artificial intelligence and machine learning, pharma has begun to realize the true implications and potential value of these technologies.

By PharmaVoice staff

AbbVie dives back into the neuro pool with a $1.2B psychedelics play

Following a major clinical failure last year, AbbVie’s purchase of a psychedelic depression treatment has the potential to revive a touch-and-go market.

By Michael Gibney • Aug. 26, 2025

FDA’s new accelerated pathway could open pharma up to risks, as well as benefits

Faster review times will leave drugmakers vulnerable to litigation, while new Trump administration priorities add more uncertainty in the drug approval process.

By Amy Baxter • Aug. 25, 2025

And just like that... pharma’s breakups reveal pain points in cancer R&D

Biotech tie-ups with Gilead, Genetech and Ipsen that have recently been let go.

By Meagan Parrish • Aug. 22, 2025

The biggest Big Pharma losers in the first half of 2025

What goes up must come down — here are the major drugs falling the hardest at the top companies so far this year.

By Michael Gibney • Aug. 21, 2025

MAHA leaders may take aim at pharma DTC advertising

RFK Jr. has his sights set on increasing advertising enforcement against pharmas, but may not come down as hard on the industry as previously thought.

By Amy Baxter • Aug. 20, 2025

Despite FDA ruling, compounded GLP-1s are still giving Novo and Lilly headaches on the market

Copycat weight loss drugs were supposed to be pulled from the market, but pharmacies have found a loophole. 

By Amy Baxter • Aug. 18, 2025

Biopharma layoffs rise as drugmakers tighten belts and reorganize

Contrary to a predicted slowdown, 2025’s layoffs are outpacing 2024.

By Kelly Bilodeau • Aug. 18, 2025

Merck KGaA ventures into new territory in the US

How the president of EMD Serono, Merck KGaA, Darmstadt, Germany’s U.S. arm, is leading the charge to “double down” on new innovation.

By Alexandra Pecci • Aug. 15, 2025

With scrapped mRNA funding, a vaccine maker finds a silver lining

While mRNA is suffering the brunt of the MAHA movement with $500 million in funding cuts, other vaccine makers could fill some of that void.

By Michael Gibney • Aug. 14, 2025

With FDA PreCheck, drugmakers may get a manufacturing boost

The newly announced program targeting domestic manufacturing is the latest Trump administration move to ramp up drugmaking in the U.S.

By Amy Baxter • Aug. 13, 2025

3 ways the GLP-1 market has changed shape this year

Novo Nordisk and Eli Lilly’s quarterly earnings revealed shifting dynamics in the lucrative obesity space.

By Amy Baxter • Aug. 12, 2025

Puerto Rico’s ongoing journey from manufacturing hub to innovation enterprise

Biotechs are coming to the island as tariffs threaten overseas drug exports, and finding Puerto Rico is more than just a leading manufacturing hub.  

By Michael Gibney • Aug. 12, 2025

Are stem cell therapies ready for pharma’s prime time?

Stem cell therapies are thriving on the fringes of healthcare — but science-backed treatments are also poised to make an impact in pharma R&D.

By Kelly Bilodeau • Aug. 11, 2025

As gene therapies falter on the market, this biopharma is aiming to defy the odds

After a strong launch for its cancer gene therapy, Ferring Pharmaceuticals is setting the stage for long-term growth.

By Meagan Parrish • Aug. 8, 2025

Inside AstraZeneca’s long-game strategy in lung cancer

New long-term results for Tagrisso in EGFR-mutated non-small cell lung cancer showcase a precision approach the company has honed for decades.

By Michael Gibney • Aug. 7, 2025

PBM reform was dropped from Trump’s spending bill. It could have saved billions.

The Senate nixed a provision to “delink” drug list prices from compensation for PBMs and other drug middlemen days before its passage.

By Alexandra Pecci • Aug. 6, 2025

David Altshuler, geneticist who helped transform Vertex, to retire next year

Since becoming Vertex's top scientist in 2015, Altshuler has helped the company become an industry powerhouse. He’ll depart next year in a “planned transition.”

By Ben Fidler • Aug. 5, 2025

Let’s make a deal? Big Pharma execs express varying views on their M&A future

Pharma executives are keeping their eyes open for dealmaking opportunities as every company has its own battles to fight.

By Michael Gibney • Aug. 5, 2025

Drugmakers score policy win in a prolonged fight against 340B

A new pilot program from HHS would alter the contentious 340B pricing program by swapping traditional upfront drug discounts for rebates.

By Amy Baxter • Aug. 4, 2025

Merck & Co. assembles an Alzheimer’s comeback with a next-gen precision focus

With two molecules in mid-stage trials, the pharma giant is taking another swing at the difficult disease with a greater understanding of its drivers.

By Michael Gibney • Aug. 1, 2025

C-suite shuffles ripple through pharma

Novo Nordisk, Kenvue and Jazz Pharmaceuticals announced changes at the top this month.

By Meagan Parrish • July 31, 2025

Dr. Vinay Prasad, controversial FDA official, abruptly departs agency

Prasad's exit ends a tumultuous tenure during which he led a reworking of agency guidelines on COVID vaccines and his office got embroiled in controversy over a Duchenne gene therapy.

By Ben Fidler • July 30, 2025

Roche pushes ahead with late-comer strategy in obesity

The Swiss pharma company announced several updates to its obesity portfolio in its latest earnings report.

By Amy Baxter • July 30, 2025